ARS Pharmaceuticals, Inc. (SPRY) earnings
SPRY earnings moved a median of -1.30% by the close. Quarterly and annual SPRY reports and results, each read against the price at its own news timestamp. Back to the SPRY overview →
29 measured SPRY earnings events.
Where these SPRY earnings landedvs 29 measured SPRY earnings reactions
| Middle 50% of SPRY earnings reactions | -3.89% to +0.34% |
|---|---|
| Median reaction (to close) | -1.30% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 SPRY earnings events with a measured close landed between -3.89% and +0.34%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results | Press release | +7.84% | +10.78% | |
| Form 10-Q ARS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +7.84% | +10.78% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results | Press release | +1.18% | +7.48% | |
| ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update | Press release | -0.81% | +0.34% | |
| Form 10-Q ARS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.81% | +0.34% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results | Press release | -0.11% | -2.70% | |
| Form 10-K ARS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.21% | -3.10% | |
| ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) | Press release | -0.30% | -11.20% | |
| Form 10-Q ARS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -0.30% | -11.20% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results | Press release | -0.78% | -3.58% | |
| ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) | Press release | -11.15% | -4.12% | |
| Form 10-Q ARS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -11.15% | -4.12% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results | Press release | -0.72% | +0.17% | |
| ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) | Press release | +5.87% | -1.30% | |
| Form 10-Q ARS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +5.87% | -1.30% | |
| ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results | Press release | -0.28% | -0.56% | |
| Form 10-K ARS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +8.91% | +16.34% | |
| ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray) | Press release | -0.48% | -1.23% | |
| Form 10-Q/A ARS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +1.71% | -5.00% | |
| ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | -5.65% | -12.60% | |
| Form 10-Q ARS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -5.65% | -12.60% | |
| ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences | Press release | +2.19% | -1.75% | |
| ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results | Press release | +4.34% | -1.19% | |
| Form 10-Q ARS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +4.34% | -1.19% | |
| ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results | Press release | -1.01% | -2.13% | |
| Form 10-Q ARS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -1.01% | -2.13% | |
| Form 10-K ARS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.58% | -3.89% | |
| ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates | Press release | +6.98% | +4.19% | |
| Form 10-Q ARS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +6.98% | +4.19% |
Keep exploring
More SPRY: analyst actions → · SEC filings → · SPRY overview →